Whitehawk Therapeutics, Inc. (WHWK)
| Market Cap | 194.92M |
| Revenue (ttm) | 7.15M |
| Net Income (ttm) | -20.60M |
| Shares Out | 47.20M |
| EPS (ttm) | -0.33 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 155,218 |
| Open | 4.100 |
| Previous Close | 4.160 |
| Day's Range | 4.094 - 4.260 |
| 52-Week Range | 1.430 - 4.480 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 7.50 (+81.6%) |
| Earnings Date | May 6, 2026 |
About WHWK
Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer. The company was formerly known as Aadi Bioscience, Inc. and changed its name to Whitehawk Therapeutics, Inc. in August 2021. Whitehawk Therapeutics, Inc. was incorporated in 2007 and is headquartered in Morristown, New Jersey. [Read more]
Financial Performance
In 2025, Whitehawk Therapeutics's revenue was $7.15 million, a decrease of -72.50% compared to the previous year's $25.98 million. Losses were -$20.60 million, -67.66% less than in 2024.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for WHWK stock is "Strong Buy." The 12-month stock price target is $7.5, which is an increase of 81.60% from the latest price.
News
Whitehawk Therapeutics Presents Comprehensive Preclinical Data Highlighting its Next-Generation ADC Portfolio at the AACR 2026
Data demonstrate preclinical proof-of-concept for HWK-007, HWK-016 and HWK-206, underpinned by Whitehawk's proprietary Carbon Bridge Cysteine Re-pairing platform Tumor regressions observed across vari...
Whitehawk Therapeutics to Participate in Jones Trading Post-AACR Fireside Chat Series
MORRISTOWN, N.J., April 16, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology...
Whitehawk Therapeutics Presents Real-World Analysis Confirming MUC16 as a Highly Expressed, Clinically Relevant Target for Gynecologic Cancers at SGO 2026
MUC16 is the highest-expressing ADC target in ovarian cancer, at least two-fold higher than other emerging targets MUC16 is highly and stably expressed in the most aggressive and most common subtypes ...
Whitehawk Therapeutics to Highlight its Next-Generation ADC Portfolio at the American Association for Cancer Research (AACR) Annual Meeting 2026
MORRISTOWN, N.J., March 17, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology...
Whitehawk Therapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
Actively recruiting Phase 1 trials for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 and MUC16-targeted ADC HWK-016 HWK-206 on track for planned IND submission in mid-2026 and Phase 1 start in Q...
Whitehawk Therapeutics Transcript: The Citizens Life Sciences Conference 2026
Three ADC programs are advancing, each targeting high-value cancer antigens with a proprietary, safer linker-payload system. Two programs are in clinical trials, with data expected in early 2027, and a third will enter the clinic in Q3. Cash reserves support operations into 2028.
Whitehawk Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing three next-generation ADC programs with a unique, highly stable platform designed to improve efficacy and safety across multiple cancer types. Early clinical data for two programs are expected in 2027, with a third entering trials in 2026, all supported by strong capital efficiency and a focus on best-in-class outcomes.
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
MORRISTOWN, N.J., Feb. 26, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology ...
Whitehawk Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Three ADC assets are advancing through clinical development, with two in Phase 1 and a third entering trials in Q3 2025. The platform offers improved potency, safety, and stability, with initial clinical data expected in H1 2027 and preclinical data releases planned for spring 2026.
Whitehawk Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
MORRISTOWN, N.J., Feb. 18, 2026 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology ...
Whitehawk Therapeutics Advances to Clinical Stage with IND Clearance for HWK-007 and Announces IND Submission for HWK-016
Actively recruiting Phase 1 trial for PTK7-targeted antibody-drug conjugate (ADC) HWK-007 IND submitted mid-December 2025 for MUC16-targeted ADC HWK-016, anticipated Phase 1 start this quarter Initial...
Whitehawk Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference
Three differentiated ADC programs are advancing to the clinic, targeting PTK7, MUC16, and SEZ6, with INDs planned by 2026 and initial clinical data expected in Q1 2027. The company is well-funded through early 2028 and aims to demonstrate best-in-class efficacy and safety across multiple solid tumor indications.
Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J. , Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an ...
Whitehawk Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference
MORRISTOWN, N.J. , Nov. 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficientl...
Whitehawk Therapeutics Transcript: Jefferies London Healthcare Conference 2025
A next-generation ADC platform is advancing three assets targeting PTK7, MUC16, and SEZ6, with INDs for two programs expected this quarter and initial clinical data anticipated in early 2027. The platform demonstrates superior potency, stability, and safety, supported by strong financials and a focus on capital efficiency.
Whitehawk Therapeutics to Present at Jefferies Global Healthcare Conference in London
MORRISTOWN, N.J. , Nov. 11, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficientl...
Whitehawk Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
MORRISTOWN, N.J. , Nov. 6, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently...
Whitehawk Therapeutics Presents Real-World Analysis Confirming PTK7 as a Broadly Expressed, Clinically Relevant Target Across Solid Tumors at AACR-NCI-EORTC
PTK7 is the third most highly expressed tumor marker among clinically validated and emerging ADC targets, present in ~70% of tumors PTK7 expression is stable across histologic subtype, disease stage a...
Tempus Announces Collaboration with Whitehawk Therapeutics to Advance Biomarker-Driven Oncology Research
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therap...
Whitehawk Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference
The company is advancing three ADC assets, with two IND filings planned for Q4 and a third in mid-2026. Lead programs target PCK7 and MUC16 with differentiated technology and biomarker strategies, aiming for broad impact in oncology. Cash reserves of $178M provide runway into early 2028.
Whitehawk Therapeutics Transcript: Morgan Stanley 23rd Annual Global Healthcare Conference
Three ADC assets are advancing into clinical trials within the next year, targeting validated but less crowded tumor antigens in oncology. The programs leverage a best-in-class linker payload platform and aim to demonstrate superior efficacy and safety, with key data readouts expected in 2026 and 2027.
Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
MORRISTOWN, N.J. , Aug. 7, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently...
Whitehawk Therapeutics to Participate in the BTIG Virtual Biotechnology Conference
MORRISTOWN, N.J. , July 22, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficientl...
Whitehawk Therapeutics Transcript: Fireside Chat
The discussion highlighted a robust ADC pipeline targeting PTK7, MUC16, and SEZ6, leveraging a next-generation linker-payload platform for improved efficacy and safety. The team emphasized disciplined capital allocation, competitive differentiation, and a clear clinical development roadmap with INDs planned through mid-2026.
Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series
MORRISTOWN, N.J. , June 19, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficientl...